StockData
Precigen, Inc. logo

Precigen, Inc. (PGEN) stock

PGENNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 2/30
$4.27−0.02 (-0.47%)

Close on Nov 18, 2026Market cap $1.53BP/E –Yield –

Precigen r&d expenses

Research and development expenses are spending on new products and technology.

Precigen's R&D Expenses for the twelve months ending Sep 30, 2019 was $379.57M, up 133.2% year over year. For fiscal 2025 it was $41.33M, down 22.1% from the year before. Over ten years it grew -5.2% a year on average. The highest annual figure on record is $404.59M in fiscal 2018.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$41.33M-22.1%
FY2024Dec 31, 2024$53.07M+9.2%
FY2023Dec 31, 2023$48.61M-88.0%
FY2018Dec 31, 2018$404.59M+182.5%
FY2017Dec 31, 2017$143.21M+27.7%
FY2016Dec 31, 2016$112.14M-24.0%
FY2015Dec 31, 2015$147.48M+150.0%
FY2014Dec 31, 2014$58.98M+22.5%
FY2013Dec 31, 2013$48.14M-24.8%
FY2012Dec 31, 2012$64.03M-8.8%
FY2011Dec 31, 2011$70.23M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$7.28M-76.9%
Q1 FY2026Mar 31, 2026$5.64M-83.7%
Q2 FY2025Jun 30, 2025$11.49M-65.3%
Q1 FY2025Mar 31, 2025$10.48M-96.3%
Q3 FY2019Sep 30, 2019$31.48M-29.9%
Q2 FY2019Jun 30, 2019$34.52M-17.9%
Q1 FY2019Mar 31, 2019$33.06M-11.3%
Q4 FY2018Dec 31, 2018$280.51M+627.8%
Q3 FY2018Sep 30, 2018$44.89M+23.1%
Q2 FY2018Jun 30, 2018$42.05M+23.6%
Q1 FY2018Mar 31, 2018$37.27M+9.0%
Q4 FY2017Dec 31, 2017$38.54M+33.5%
Q3 FY2017Sep 30, 2017$36.47M+25.6%
Q2 FY2017Jun 30, 2017$34.01M–
Q1 FY2017Mar 31, 2017$34.18M–
Q4 FY2016Dec 31, 2016$28.87M–
Q3 FY2016Sep 30, 2016$29.04M–

More Precigen figures

See a number that looks wrong?